Troponin Testing Decision
No, troponin testing is not indicated for this patient based on the clinical presentation of isolated respiratory symptoms (shortness of breath, wheezing, cough) without chest pain and a normal ECG.
Clinical Reasoning
The 2014 AHA/ACC guidelines are explicit: cardiac troponin should be measured "in all patients who present with symptoms consistent with ACS" 121. The critical question here is whether this patient's presentation is "consistent with ACS."
Why This Patient Does Not Meet Criteria for Troponin Testing
Primary presentation is respiratory, not cardiac:
- The dominant symptoms are wheezing and cough—classic bronchospastic/pulmonary findings
- Shortness of breath in isolation, particularly when accompanied by wheezing, suggests reactive airway disease, asthma exacerbation, or other pulmonary pathology
- Absence of chest pain is significant—this is the hallmark symptom that triggers ACS evaluation
Normal ECG provides reassurance:
- The guidelines emphasize that risk stratification should integrate "history, ECG findings, and cardiac biomarkers" 13
- A normal ECG in a patient without chest pain or anginal equivalent symptoms substantially lowers pre-test probability for ACS
What the Evidence Shows About Non-Chest Pain Presentations
Research demonstrates that troponin testing in patients without chest pain or ischemic ECG changes has limited clinical utility:
- In one study, 63.3% of patients with elevated troponins had neither chest pain nor ischemic ECG changes, and these elevations resulted in no coronary interventions or treatment of life-threatening arrhythmias 4
- Another study found that only 3.6% of patients presenting without chest pain had elevated troponin, and when elevated, it was associated with non-cardiac causes and higher mortality from comorbid conditions 5
- Patients with "anginal equivalent symptoms" (like isolated dyspnea) rarely received ACS diagnoses unless troponin was ≥2 μg/L 6
The Appropriate Clinical Pathway
For this 30-minute episode with respiratory symptoms:
Focus on the pulmonary differential diagnosis:
- Asthma/reactive airway disease
- Bronchitis
- Pulmonary embolism (if risk factors present—would warrant D-dimer, not troponin)
- COPD exacerbation
Treat the bronchospasm:
- Bronchodilators
- Consider corticosteroids if indicated
- Assess response to therapy
Reserve troponin testing for specific scenarios:
- Development of chest pain or pressure
- ECG changes suggesting ischemia
- Clinical deterioration suggesting cardiac etiology
- High pre-test probability for ACS based on risk factors AND symptoms evolving to suggest cardiac origin
Important Caveats
Do not reflexively order troponin just because a patient has shortness of breath. The 2021 AHA/ACC Chest Pain Guidelines emphasize using clinical decision pathways that incorporate symptoms, ECG, and risk stratification 78.
Shortness of breath alone is not an indication for troponin testing unless:
- It represents an anginal equivalent in a patient with known CAD
- It occurs with other features suggesting ACS (diaphoresis, nausea, radiation)
- The clinical context suggests acute decompensated heart failure with possible underlying ACS
The Risk of Unnecessary Testing
Ordering troponin in low-probability scenarios leads to:
- False positive results requiring unnecessary downstream testing
- Increased healthcare costs without improving outcomes 4
- Potential for incidental findings that don't change management
- Delayed diagnosis of the actual problem (in this case, likely pulmonary)
Bottom line: Treat the wheezing and cough as a primary respiratory problem. Only pursue cardiac biomarkers if the clinical picture evolves to suggest ACS or if the patient fails to respond to appropriate respiratory therapy.